Results 221 to 230 of about 789,870 (314)

The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities. [PDF]

Curr Oncol
Bongiovanni A, Conte P, Conteduca V, Landriscina M, Di Lorenzo G, Cognetti F.   +5 more
europepmc   +1 more source

Coupling of Homologous Recombination and the Checkpoint by ATR.

Molecules and Cells, 2017
R. Buisson, Joshi Niraj, Amélie Rodrigue, Chu Kwen Ho, J. Kreuzer, T. Foo, Émilie J.-L. Hardy, G. Dellaire, W. Haas, B. Xia, J. Masson, L. Zou   +11 more
semanticscholar   +1 more source

Clinical and Genetic Significance of Chromosomal Microarray Screening of Asymptomatic Newborns

Journal of Clinical Laboratory Analysis, EarlyView.
Among 99 asymptomatic newborns with abnormal low‐resolution chromosomal microarray (LR‐CMA) screening, 70.7% harbored microduplication/microdeletions with syndromic implications. However, only a minority exhibited developmental concerns during early follow‐up, highlighting the need for cautious interpretation.
Naye Choi, Hwa Young Kim, Jung Min Ko
wiley   +1 more source

Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples. [PDF]

PLoS One
Li W, Leibowitz JA, Wang S, Walker L, Xu C, Chen KT, Schrock AB, Hughes J, Patel N, Elvin JA, Ritterhouse LL, Sokol E, Frampton G, Dennis L, Yilmazel B, Decker B.   +15 more
europepmc   +1 more source

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Cancer Discovery, 2015
P. Konstantinopoulos, Raphael Ceccaldi, G. Shapiro, A. D’Andrea   +3 more
semanticscholar   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

The Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol, Jason H. Williams, Haihong Shi, Derek Z. Yang, Justin Hoffman, Diane D. Wang   +5 more
wiley   +1 more source

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Cold Spring Harbor Perspectives in Biology, 2015
Rohit Prakash, Yu Zhang, Weiran Feng, M. Jasin   +3 more
semanticscholar   +1 more source

HMGB1 Assists in Overcoming Cisplatin Resistance in Chemoresistant Human Ovarian Cancer Cells

Molecular Carcinogenesis, EarlyView.
ABSTRACT Cisplatin is one of the most effective chemotherapeutic agents used in the treatment of ovarian cancer. However, the frequent development of cisplatin resistance remains a significant limitation, leading to therapeutic failure and poor patient outcomes.
Van Huynh, Guliang Wang, Anirban Mukherjee, Karen M. Vasquez   +3 more
wiley   +1 more source

Homologous Recombination Deficiency Testing in Women With Ovarian Cancer: An Egyptian Multicentre Study. [PDF]

BJOG
Shohdy KS, Kassem L, Gabriel B, Barsoum E, Elnahas T, Azim HA.   +5 more
europepmc   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source